Halozyme Therapeutics Quarterly Balance Sheet
NASDAQ: HALOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Halozyme Therapeutics financial position
As of Jun 30, 2026, Halozyme Therapeutics reported total assets of $2.58 billion, up 25.5% from a year earlier against total liabilities of $2.43 billion. Shareholders' equity stood at $143.5 million, or 5.6% of assets. The company held $163.1 million in cash and equivalents against $2.15 billion of debt, a net debt position of $1.98 billion.
The current ratio (current assets divided by current liabilities) was 2.71, meaning short-term assets cover obligations due within a year. Debt-to-equity was 14.95.
Summary generated from market data by MetaCap's automated system. Methodology
Halozyme Therapeutics balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 163.14M | 309.75M | 133.82M | 419.67M | 61.86M | 176.33M | 115.85M | 154.32M | 187.86M | 164.63M | 118.37M | 274.23M |
| Receivables | 453.33M | 457.99M | 426.27M | 343.54M | 315.07M | 304.02M | 288.20M | 273.06M | 210.42M | 185.31M | 233.25M | 213.99M |
| Inventory | 137.13M | 155.47M | 176.47M | 185.80M | 181.50M | 164.87M | 141.86M | 131.41M | 159.31M | 168.54M | 127.60M | 128.92M |
| Total Current Assets | 933.02M | 1.00B | 825.21M | 1.33B | 1.12B | 1.26B | 1.09B | 1.13B | 987.80M | 873.58M | 746.42M | 879.01M |
| Property, Plant & Equipment | 49.76M | 46.93M | 44.44M | 40.58M | 39.60M | 40.22M | 40.86M | 39.98M | 40.21M | 41.89M | 38.11M | 37.47M |
| Goodwill | 581.73M | 582.32M | 580.36M | 416.82M | 416.82M | 416.82M | 416.82M | 416.82M | 416.82M | 416.82M | 416.82M | 416.82M |
| Intangible Assets | 922.44M | 951.96M | 981.47M | 348.54M | 366.31M | 384.07M | 401.83M | 419.59M | 437.35M | 455.12M | 472.88M | 490.64M |
| Total Assets | 2.58B | 2.67B | 2.53B | 2.22B | 2.05B | 2.20B | 2.06B | 2.12B | 1.97B | 1.84B | 1.73B | 1.89B |
| Accounts Payable | 23.61M | 14.10M | 20.90M | 15.36M | 18.69M | 20.07M | 10.25M | 12.40M | 15.43M | 13.32M | 11.82M | 19.32M |
| Short-Term Debt | 208.97M | 208.74M | 0 | 710.68M | — | — | 0 | — | — | — | 0 | 0 |
| Total Current Liabilities | 344.44M | 363.21M | 177.09M | 837.23M | 134.28M | 150.38M | 139.10M | 108.81M | 133.36M | 131.64M | 112.49M | 115.19M |
| Long-Term Debt | 1.94B | 1.94B | 2.14B | 800.07M | 1.51B | 1.51B | 1.51B | 1.50B | 1.50B | 1.50B | 1.50B | 1.50B |
| Total Liabilities | 2.43B | 2.45B | 2.48B | 1.72B | 1.72B | 1.71B | 1.70B | 1.67B | 1.68B | 1.66B | 1.65B | 1.64B |
| Shareholders' Equity | 143.54M | 219.64M | 48.81M | 503.92M | 332.75M | 482.27M | 363.82M | 452.70M | 289.42M | 177.81M | 83.81M | 249.18M |
| Retained Earnings | 151.26M | 204.84M | 54.79M | 502.15M | 361.03M | 477.96M | 359.87M | 397.63M | 260.62M | 167.37M | 90.55M | 222.28M |
| Total Debt | 2.15B | 2.14B | 2.14B | 1.51B | 1.51B | 1.51B | 1.51B | 1.50B | 1.50B | 1.50B | 1.50B | 1.50B |
| Net Cash (Debt) | -1.98B | -1.83B | -2.01B | -1.09B | -1.45B | -1.33B | -1.39B | -1.35B | -1.31B | -1.34B | -1.38B | -1.22B |
| Shares Outstanding | 114.04M | 118.52M | 117.78M | 117.52M | 117.62M | 123.17M | 123.14M | 127.18M | 126.53M | 127.19M | 126.77M | 132.08M |
This table shows 12 quarterly periods of Halozyme Therapeutics's balance sheet, from Q2 2026 back to Q3 2023, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow HALO's reporting calendar. What is a balance sheet?